Janux Therapeutics (JANX) Stock Price, News & Analysis

Company Overview

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies. Its development programs have included product candidates directed at targets such as prostate-specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR).

Founded in 2017 and headquartered in San Diego, California, Janux Therapeutics became a publicly traded company on the Nasdaq under the symbol JANX in 2024. The company’s programs are in clinical and preclinical development, and its activities are primarily centered on research and development in the United States. Janux is led by Chief Executive Officer David O’Neil.

Key Stats

• Today's Range: $12.43 to $17.95
• 50-Day Range: $12.76 to $20.24
• 52-Week Range: $12.12 to $35.34
• Volume: 4.85 million shs
• Average Volume: 755,955 shs
• Market Capitalization: $780.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.92
• Consensus Rating: Moderate Buy

Janux Therapeutics Stock Analysis - MarketRank™

Janux Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 238th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Janux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Janux Therapeutics has a consensus price target of $36.92, representing about 189.4% upside from its current price of $12.76.

Amount of Analyst Coverage

Janux Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.70) to ($2.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Janux Therapeutics is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Janux Therapeutics is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Janux Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.46% of the float of Janux Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Janux Therapeutics has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Janux Therapeutics has recently decreased by 6.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Janux Therapeutics does not currently pay a dividend.

Dividend Growth

Janux Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.68

News Sentiment

Janux Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Janux Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

6 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Janux Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.90% of the stock of Janux Therapeutics is held by insiders.

Percentage Held by Institutions

75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/09/2026
• Study update: 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:JANX
• CIK: 1817713
• Web: www.januxrx.com
• Phone: 858-751-4493
• Fax: N/A
• Employees: 113
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Janux Therapeutics: $36.92
• High Price Target: $100.00
• Low Price Target: $15.00
• Potential Upside/Downside: +189.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.62 million
• Net Margins: N/A
• Pretax Margin: -427.47%
• Return on Equity: -11.89%
• Return on Assets: -11.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.35
• Quick Ratio: 16.35

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 78.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.91 per share
• Price / Book: 0.80

Miscellaneous

• Outstanding Shares: 61,140,000
• Free Float: 56,307,000
• Market Cap: $780.15 million
• Optionable: Optionable
• Beta: 2.44